TY - JOUR
T1 - Biomimetic Tissue Engineering
T2 - Tuning the Immune and Inflammatory Response to Implantable Biomaterials
AU - Taraballi, Francesca
AU - Sushnitha, Manuela
AU - Tsao, Christopher
AU - Bauza, Guillermo
AU - Liverani, Chiara
AU - Shi, Aaron
AU - Tasciotti, Ennio
N1 - Funding Information:
F.T. and M.S. contributed equally to this work. This work was supported financially by Hearst Foundation (Project ID, 18130017), the Cullen Trust for Health Care Foundation (Project ID, 18130014), and the DoD USAMRMC (Project ID, W81XWH-15-1-0718). The authors would also like to thank Dr. Jonathan Martinez and Michael Evangelopoulos in the preparation of this manuscript.
Publisher Copyright:
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2018/9/5
Y1 - 2018/9/5
N2 - Regenerative medicine technologies rely heavily on the use of well-designed biomaterials for therapeutic applications. The success of implantable biomaterials hinges upon the ability of the chosen biomaterial to negotiate with the biological barriers in vivo. The most significant of these barriers is the immune system, which is composed of a highly coordinated organization of cells that induce an inflammatory response to the implanted biomaterial. Biomimetic platforms have emerged as novel strategies that aim to use the principle of biomimicry as a means of immunomodulation. This principle has manifested itself in the form of biomimetic scaffolds that imitate the composition and structure of biological cells and tissues. Recent work in this area has demonstrated the promising potential these technologies hold in overcoming the barrier of the immune system and, thereby, improve their overall therapeutic efficacy. In this review, a broad overview of the use of these strategies across several diseases and future avenues of research utilizing these platforms is provided.
AB - Regenerative medicine technologies rely heavily on the use of well-designed biomaterials for therapeutic applications. The success of implantable biomaterials hinges upon the ability of the chosen biomaterial to negotiate with the biological barriers in vivo. The most significant of these barriers is the immune system, which is composed of a highly coordinated organization of cells that induce an inflammatory response to the implanted biomaterial. Biomimetic platforms have emerged as novel strategies that aim to use the principle of biomimicry as a means of immunomodulation. This principle has manifested itself in the form of biomimetic scaffolds that imitate the composition and structure of biological cells and tissues. Recent work in this area has demonstrated the promising potential these technologies hold in overcoming the barrier of the immune system and, thereby, improve their overall therapeutic efficacy. In this review, a broad overview of the use of these strategies across several diseases and future avenues of research utilizing these platforms is provided.
KW - foreign body reactions
KW - immune tuning materials
KW - implantable devices
KW - inflammation
KW - materials functionalization
UR - http://www.scopus.com/inward/record.url?scp=85050405237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050405237&partnerID=8YFLogxK
U2 - 10.1002/adhm.201800490
DO - 10.1002/adhm.201800490
M3 - Article
C2 - 29995315
AN - SCOPUS:85050405237
VL - 7
JO - Advanced Healthcare Materials
JF - Advanced Healthcare Materials
SN - 2192-2640
IS - 17
M1 - 1800490
ER -